Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Project Oncology®
Optimizing First-Line Care for PD-L1–Low Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP; Deepa Rangachari, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Deepa Rangachari, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP; Stacey Cohen, MD
- Brian P. McDonough, MD, FAAFP
- Stacey Cohen, MD
Communicating Pathologic Response Results in Resectable NSCLC
Communicating Pathologic Response Results in Resectable NSCLC
Project Oncology®
Communicating Pathologic Response Results in Resectable NSCLC
Charles Turck, PharmD, BCPS, BCCCP; Alexander Spira, MD, PhD, FACP
- Charles Turck, PharmD, BCPS, BCCCP
- Alexander Spira, MD, PhD, FACP
- Robert Merritt, MD
Managing High-Risk Subgroups in Metastatic NSCLC
Managing High-Risk Subgroups in Metastatic NSCLC
Project Oncology®
Managing High-Risk Subgroups in Metastatic NSCLC
Charles Turck, PharmD, BCPS, BCCCP; Melina Marmarelis, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Melina Marmarelis, MD
- Deepa Rangachari, MD
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Project Oncology®
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Charles Turck, PharmD, BCPS, BCCCP; Laura Alder, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Laura Alder, MD
- Christine Bestvina, MD
Emerging Therapeutic Strategies in Metastatic NSCLC
Emerging Therapeutic Strategies in Metastatic NSCLC
Project Oncology®
Emerging Therapeutic Strategies in Metastatic NSCLC
Brian P. McDonough, MD, FAAFP; Urs Weber, MD
- Brian P. McDonough, MD, FAAFP
- Urs Weber, MD
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Project Oncology®
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Alexandria May, PharmD, BCPS; Adam Brufsky, MD, PhD
- Alexandria May, PharmD, BCPS
- Adam Brufsky, MD, PhD
Addressing Barriers to CAR T Referral in R/R LBCL
Addressing Barriers to CAR T Referral in R/R LBCL
Project Oncology®
Addressing Barriers to CAR T Referral in R/R LBCL
Steve Jackson, PharmD; Matthew J. Matasar, MD
- Steve Jackson, PharmD
- Matthew J. Matasar, MD
- Tycel Phillips, MD

Medical News

Medical News
Amivantamab Plus Lazertinib in EGFR-Mutant Lung Cancer with CNS Metastases
05/28/2026
Read more
Medical News
Molecular Profiling Guides Adjuvant Therapy in Endometrial Cancer
05/25/2026
Read more
Medical News
BCG Plus Mitomycin Fails to Improve DFS in ANZUP 1301
05/22/2026
Read more
Medical News
Early Postoperative Intake Linked To Complications After GI Cancer Surgery
05/19/2026
Read more

CME/CE

コンテキストにおける意思決定：脳転移に対する全身療法およびCNS療法の順序決定に関する実践的枠組み
コンテキストにおける意思決定：脳転移に対する全身療法およびCNS療法の順序決定に関する実践的枠組み
CME/CE
コンテキストにおける意思決定：脳転移に対する全身療法およびCNS療法の順序決定に関する実践的枠組み
Barbara O'Brien, MD
0.25 credits
- Barbara O'Brien, MD
0.25 credits
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CE
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE; Samir Dalia, MD
0.25 credits
- Joseph Kim, MD, MPH, MBA, FACHE
- Samir Dalia, MD
- Christopher Jurief
0.25 credits
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
MinuteCE®
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
Barbara O'Brien, MD; Nadia Harbeck, MD, PhD
1.00 program credit
- Barbara O'Brien, MD
- Nadia Harbeck, MD, PhD
1.00 program credit

Clinical Practice

Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
CME/CE
Making the Right Moves in Metastatic CSPC: Intensification, Imaging, and Impact
Neeraj Agarwal, MD, FASCO; Rana McKay, MD
0.25 credits
- Neeraj Agarwal, MD, FASCO
- Rana McKay, MD
0.25 credits
Shared Decision-Making in Colorectal Cancer Screening
Shared Decision-Making in Colorectal Cancer Screening
Clinician's Roundtable
Shared Decision-Making in Colorectal Cancer Screening
Gates B. Colbert, MD; Sarina Schrager, MD
- Gates B. Colbert, MD
- Sarina Schrager, MD
- Lashika Yogendran, MD
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Project Oncology®
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Charles Turck, PharmD, BCPS, BCCCP; Daniel Geynisman, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Geynisman, MD
- Jonathan Henderson, MD
Optimizing Multidisciplinary Care in Perioperative NSCLC
Optimizing Multidisciplinary Care in Perioperative NSCLC
Project Oncology®
Optimizing Multidisciplinary Care in Perioperative NSCLC
Steve Jackson, PharmD; David Tom Cooke, MD, FACS
- Steve Jackson, PharmD
- David Tom Cooke, MD, FACS
- Joshua Reuss, MD

Programs

Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
COVID-19: On The Frontlines
Turning Cold Tumors Hot with mRNA COVID-19 Vaccines
Hallie Blevins, PhD; Marlene Mimi Maeusli, PhD.
- Hallie Blevins, PhD
- Marlene Mimi Maeusli, PhD.
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Project Oncology®
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD; Raghava Reddy Induru, MD
- Steve Jackson, PharmD
- Raghava Reddy Induru, MD
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Clinician's Roundtable
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Peter Buch, MD, FACG, AGAF, FACP; Aasma Shaukat, MD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Project Oncology®
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP; Bilal Siddiqui, MD
- Brian P. McDonough, MD, FAAFP
- Bilal Siddiqui, MD